as 07-26-2024 4:00pm EST
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | EMERYVILLE |
Market Cap: | 1.5B | IPO Year: | 2004 |
Target Price: | $25.33 | AVG Volume (30 days): | 2.0M |
Analyst Decision: | Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.06 | EPS Growth: | -96.18 |
52 Week Low/High: | $10.23 - $15.15 | Next Earning Date: | 08-06-2024 |
Revenue: | $236,149,000 | Revenue Growth: | -63.98% |
Revenue Growth (this year): | 25.08% | Revenue Growth (next year): | 22.51% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
CANO FRANCIS | DVAX | Director | May 31 '24 | Sell | $11.93 | 3,615 | $43,126.95 | 36,905 | SEC Form 4 |
Burgess Justin | DVAX | Chief Accounting Officer | Mar 1 '24 | Sell | $12.78 | 7,101 | $90,750.78 | 13,425 | SEC Form 4 |
Burgess Justin | DVAX | Chief Accounting Officer | Mar 1 '24 | Sell | $12.78 | 13,425 | $171,571.50 | 0 | SEC Form 4 |
Janssen Robert | DVAX | SVP and CMO | Jan 4 '24 | Sell | $15.00 | 1,500 | $22,500.00 | 49,925 | SEC Form 4 |
Novack David F | DVAX | President & COO | Jan 2 '24 | Sell | $14.45 | 9,000 | $130,050.00 | 3,187 | SEC Form 4 |
Novack David F | DVAX | President & COO | Dec 1 '23 | Sell | $13.56 | 20,000 | $271,200.00 | 3,187 | SEC Form 4 |
Novack David F | DVAX | President & COO | Nov 3 '23 | Sell | $15.00 | 20,000 | $300,000.00 | 3,187 | SEC Form 4 |
DVAX Breaking Stock News: Dive into DVAX Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
PR Newswire
3 days ago
Argus Research
10 days ago
Argus Research
17 days ago
Argus Research
24 days ago
Clinical Trials Arena
a month ago
MT Newswires
a month ago
PR Newswire
a month ago
The information presented on this page, "DVAX Dynavax Technologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.